Entyvio and Paleness - a phase IV clinical study of FDA data

Summary:

Paleness is reported as a side effect among people who take Entyvio (vedolizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Tylenol, and have Ulcerative colitis.

The phase IV clinical study analyzes which people have Paleness when taking Entyvio. It is created by eHealthMe based on reports of 23,685 people who have side effects when taking Entyvio from the FDA, and is updated regularly.

What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 23,827 Entyvio users. Check the latest studies of Entyvio.

What is Paleness?

Paleness (unusual lightness of skin colour) is found to be associated with 1,566 drugs and 2,116 conditions by eHealthMe. Check the latest studies of Paleness.

On Jul, 19, 2026

23,685 people reported to have side effects when taking Entyvio.
Among them, 63 people (0.27%) have Paleness.

Among these 63 people:

How long have people been on Entyvio when they have Paleness? *

What is the gender of people who have Paleness when taking Entyvio? *

female: 62.71 %
male: 37.29 %

What is the age of people who have Paleness when taking Entyvio? *

What are other drugs people take besides Entyvio? *

What are other side effects people have besides Paleness? *

Fatigue (feeling of tiredness): 30 people, 47.62%
High Blood Pressure: 23 people, 36.51%
Dizziness: 21 people, 33.33%
Malaise (a feeling of general discomfort or uneasiness): 17 people, 26.98%
Heart Rate Increased: 17 people, 26.98%
Diarrhea: 17 people, 26.98%
Hypotension (abnormally low blood pressure): 16 people, 25.40%
Fever: 16 people, 25.40%
Nausea (feeling of having an urge to vomit): 15 people, 23.81%
Poor Venous Access: 14 people, 22.22%

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 36 people, 57.14%
Abdominal Discomfort: 6 people, 9.52%
Psoriasis (immune-mediated disease that affects the skin): 5 people, 7.94%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 6.35%
Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 3 people, 4.76%
Anaemia (lack of blood): 3 people, 4.76%
Neuropathy Peripheral (surface nerve damage): 3 people, 4.76%
Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 3 people, 4.76%
Peripheral Motor Neuropathy (muscles in the body become progressively weaker over months to years): 2 people, 3.17%
Prostate Cancer: 2 people, 3.17%

* Approximation only. Some reports may have incomplete information.

Do you take Entyvio and have Paleness?

- Check whether Paleness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Entyvio:

Entyvio (23,827 reports)

Paleness treatments and more:

Paleness (34,670 reports)

Browse all side effects of Entyvio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paleness:

Paleness (1,566 drugs)

Browse all the conditions that are associated with Paleness:

Paleness (2,116 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vedolizumab (the active ingredients of Entyvio) and Entyvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.